MTOR and meningioma: The comprehensive review highlights these problems and emphasizes the need for well-designed clinical studies to determine the safety and efficacy of these combinations.[64] A Phase II study in patients with aggressive meningioma investigated the efficacy of the combination of the mTOR inhibitor everolimus and the somatostatin agonist octreotide in patients with meningioma.